Previous Close | 0.1900 |
Open | 0.1900 |
Bid | 0.0000 |
Ask | 0.0100 |
Strike | 390.00 |
Expire Date | 2024-05-03 |
Day's Range | 0.1900 - 0.1900 |
Contract Range | N/A |
Volume | |
Open Interest | 151 |
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeTreasury Rally Risks Running Into a $125 Billion Brick WallFrance’s Macron Calls for Reset of Economic Ties With ChinaLamborghini Bros No More: Crypto Is Creating a New Wealth EffectThe shares
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.